tradingkey.logo

scPharmaceuticals Inc

SCPH
View Detailed Chart
5.670USD
0.000
Close 11/07, 16:00ETQuotes delayed by 15 min
302.16MMarket Cap
LossP/E TTM

scPharmaceuticals Inc

5.670
0.000
Intraday
1m
30m
1h
D
W
M
D

Today

0.00%

5 Days

0.00%

1 Month

0.00%

6 Months

+135.27%

Year to Date

+60.17%

1 Year

+31.25%

View Detailed Chart

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite a very weak market performance, the company shows strong fundamentals and technicals.

scPharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking
99 / 174
Overall Ranking
263 / 4702
Industry
Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 0 analysts
--
Current Rating
12.088
Target Price
+113.18%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

scPharmaceuticals Inc Highlights

StrengthsRisks
scPharmaceuticals Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The Company develops, internally and through strategic partnerships, products and solutions that aim to expand and advance the outpatient care of select acute conditions. Its lead product candidate, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infuser. FUROSCIX is a formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self- administered subcutaneously via a single-use, disposable and wearable on-body delivery system. The Companay’s pipeline programs include SCP-111 (furosemide injection) 80mg/mL is an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home.
Growing
The company is in a growing phase, with the latest annual income totaling USD 36.33M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 131.14.
Fairly Valued
The company’s latest PE is 0.00, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 43.14M shares, decreasing 13.57% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 1.84M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 3.31.

scPharmaceuticals Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

scPharmaceuticals Inc Info

scPharmaceuticals Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The Company develops, internally and through strategic partnerships, products and solutions that aim to expand and advance the outpatient care of select acute conditions. Its lead product candidate, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infuser. FUROSCIX is a formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self- administered subcutaneously via a single-use, disposable and wearable on-body delivery system. The Companay’s pipeline programs include SCP-111 (furosemide injection) 80mg/mL is an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home.
Ticker SymbolSCPH
CompanyscPharmaceuticals Inc
CEOMr. John H. Tucker
Websitehttps://www.scpharmaceuticals.com/
KeyAI